OKYO Pharma filed its annual report for fiscal year ending March 31, 2026, highlighting a strengthened cash position of $20.6 million after raising about $25 million in the year. This financial boost supports the upcoming global Phase 3 NEPTUNE trial for its lead drug urcosimod, aimed at treating neuropathic corneal pain. The trial, planned for late 2026, will enroll 111 patients in the US and Europe and follows positive FDA feedback, positioning OKYO for potential drug registration and long-term value creation for patients and shareholders.
The U.S. Bankruptcy Court for the Central District of California confirmed the Plan of Liquidation for Oceanwide Plaza LLC, enabling the $470 million sale of the stalled Downtown Los Angeles development to KPC Square, a joint venture between KPC Grou...
Axsome Therapeutics received an "Outperform" rating from BMO Capital due to significant progress in its drug pipeline, including FDA acceptance of its NDA for AXS-12, a narcolepsy treatment with a PDUFA date set for May 1, 2027. The company is also a...
Novartis is set to report its Q2 earnings with analysts expecting an EPS of $2.17 and revenue of $14.07 billion, following a tough Q1 affected by major patent expirations. Despite revenue challenges, the company maintained strong cash flow of $3.30 b...
Spain won the 2026 FIFA World Cup, a victory spotlighting Chiliz’s fan token ecosystem as both Spain and Argentina—finalists—are Chiliz partners. This marks the first World Cup final between two fan token nations, showcasing tokenized fan engagement'...
Margin debt in the U.S. increased for the third consecutive month in June, reaching a record $1.53 trillion. This represents a 7.9% rise from May and a 51.5% increase compared to June last year. Adjusted for inflation, the growth remains significant ...
